Introduction
Heart failure (HF) is a leading reason for hospitalization in Western populations over the age of 65 years and is associated with significant cost, morbidity and subsequent mortality.
1 Precipitating factors leading to HF hospitalization have been identified in prior, mainly retrospective, studies and include arrhythmias, myocardial ischaemia, infections, worsening renal function, uncontrolled hypertension and non-compliance with medications or diet.
2 -5 However, the relationships between these factors and long-term morbidity and mortality, including recurrent hospitalizations, are not well understood. Similarly, the clinical signs and symptoms on admission in patients hospitalized for HF according to these precipitants are poorly described.
A better understanding of the effects of factors precipitating HF hospitalizations is important for several reasons. Firstly, the identification of modifiable factors leading to HF hospitalizations may help inform strategies to mitigate recurrent admission. Secondly, the association of these factors with recurrent hospitalizations may inform the design of future clinical trials in, for instance, the selection of high-risk patient populations. Traditionally, only the first hospitalization for HF has been analysed as an endpoint in clinical trial reports and observational studies. However, this approach does not consider the burden of recurrent events to patients, the healthcare system and payers. Analyses of recurrent hospitalizations among patients with HF are thus gaining increasing interest and have the potential to improve the efficiency and reduce the cost of future clinical trials. 6, 7 In this study, we examined prospectively collected, investigator-identified factors thought to have contributed to the first hospitalization for HF in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme and the associations between these contributors to HF hospitalization and subsequent recurrent admissions, as well as the rate and causes of subsequent death. As the literature on the precipitants of HF hospitalization in individuals with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) is sparse, these variables were also stratified by ejection fraction (EF) and examined.
Methods

Patient population
In the CHARM programme, 7599 patients with New York Heart Association (NYHA) class II-IV HF were randomized to candesartan or placebo in addition to standard HF therapy. The design and main results of this trial have been previously reported. 8 Briefly, the programme consisted of three concurrent trials (running from March 1999 to March 2003): CHARM-Alternative included HF patients with an EF of ≤40% who were intolerant to angiotensin-converting enzyme (ACE) inhibitors; CHARM-Added included HF patients with an EF of ≤40% who were being treated with an ACE inhibitor, and CHARM-Preserved included HF patients with an EF of >40%, most of whom were not treated with an ACE inhibitor. The CHARM trials were approved by the institutional review boards at each study site and all enrolled patients provided informed consent. if there was no primary precipitating factor reported for the first adjudicated HF hospitalization (n = 7) or if the EF was not documented (n = 1). The present analysis focused on patients with a first adjudicated HF hospitalization (n = 1668).
Outcomes
The primary outcome of the overall programme was all-cause mortality. Primary outcomes for the component trials were the composite of cardiovascular (CV) death or hospital admission for HF. First hospitalizations for HF were adjudicated, whereas subsequent HF hospitalizations were investigator-reported, as were non-HF hospitalizations. The median follow-up for the overall programme was 37.7 months. Because of uncertain discharge dates, data for two patients were excluded from the annual incidence rates for HF, CV, non-CV and all-cause readmissions. For patients with missing discharge dates for the first HF hospitalization (n = 141), discharge dates were imputed assuming a 5-day length of stay based on the median hospital length of stay in this trial. Data for patients who ended the study while hospitalized (n = 7) were not used in the calculation of annual incidence rates for HF, CV, non-CV and all-cause readmissions.
Identification of precipitating factors
When reporting HF hospitalizations after randomization, investigators were asked to report possible precipitating and aggravating factors and to assign a primary reason for the HF hospitalization from among several predefined reasons: non-compliance with cardiac medications; inappropriate decrease of anti-failure therapy; excessive salt intake/dietary non-compliance; cardiac arrhythmias; acute myocardial ischaemia/myocardial infarction; anaemia; febrile illness; other high-output state; excessive alcohol intake; concomitant drug use within the previous 48 h (calcium channel blockers, beta-blockers, antiarrhythmic drugs other than amiodarone, non-steroidal anti-inflammatory drugs); any other non-cardiac precipitating or associated illness or factor; precipitating valvular disease, and any other precipitating or aggravating factor(s). Only the primary precipitant identified by investigators was utilized in this analysis. For first adjudicated HF hospitalizations attributed to either 'any other non-cardiac precipitating or associated illness or factor' (n = 282) or 'any other precipitating or aggravating factor(s)' (n = 543), free-text descriptions of the primary reason were individually reviewed by a physician and used to reclassify the precipitating factors into specific CV, non-CV and unknown factors.
Statistical analyses
Baseline characteristics of patients according to precipitant factor were compared using chi-squared or Fisher's exact tests, as appropriate, for categorical variables, and analyses of variance (ANOVA) for continuous variables. In additional analyses, investigator-identified clinical characteristics (HF signs and symptoms) and precipitating factors for HF hospitalizations, stratified by those with reduced (≤40%) and preserved (>40%) EF, were analysed using chi-squared or Fisher's exact tests, as appropriate.
To assess possible associations between precipitating factors leading to the first HF hospitalization and subsequent hospitalizations and mortality, incident all-cause readmission rates were compared across the three precipitating factor groups, stratified by EF group, using chi-squared or Fisher's exact tests, as appropriate. To assess the cumulative incidence rates of subsequent HF hospitalization, the crude number of HF hospitalizations per 100 patient-years of follow-up after discharge from the initial hospitalization for HF was calculated by dividing the total number of HF hospitalizations by the total follow-up time of all patients in each group. The resulting incidence rates, 95% confidence intervals (CIs) and P-values were based on the Poisson distribution. 9 All tests were two-sided. P-values of <0.05 were considered to indicate differences of statistical significance. All analyses were conducted using STATA SE version 12.1 (StataCorp LLC, College Station, TX, USA).
Results
Baseline characteristics according to type of precipitant
Overall, 1668 patients enrolled in the CHARM programme and hospitalized for HF based on adjudication criteria were included in this analysis. Their baseline characteristics, according to type of precipitant, are presented in Table 1 . Investigators identified a probable CV precipitant in 54% (n = 895) of first HF hospitalizations, a non-CV precipitant in 32% (n = 538) and were unable to identify any precipitant (precipitant unknown) in 14% (n = 235). Baseline characteristics were broadly similar across the three groups. Of all patients hospitalized for HF, 1152 (69%) had HFrEF at baseline and 516 (31%) had HFpEF.
Investigator-identified factors precipitating heart failure hospitalization
Among the CV precipitants, the five most commonly reported reasons in the HFrEF and HFpEF groups, respectively, were: (i) an arrhythmia (15% vs. 16% of all precipitants; 27% vs. 31% of CV precipitants); (ii) non-compliance/inappropriate decrease in HF therapy (11% vs. 8%); (iii) dietary indiscretion/excessive oral or i.v. fluids (8% vs. 9%); (iv) myocardial ischaemia/angina (7% vs. 9%), and (v) worsening HF/disease progression (9% vs. 3%; P < 0.001) ( Table 2) . Although uncommon, uncontrolled hypertension was more often identified as a precipitant in patients with HFpEF (in 3% of admissions) than in those with HFrEF (1%) (P = 0.007).
Among the non-CV reasons for admission, respiratory infection was by far the most common individual precipitant (10% vs. 11% of all precipitants; 32% vs. 33% of non-CV precipitants). Worsening renal function (3% vs. 5%), other infection (2% vs. 3%) and anaemia (1% vs. 3%; P = 0.018) represented the other most commonly identified precipitants. Although less common, a diabetes-related reason was more commonly reported as a precipitating factor in HFpEF (0.2% vs. 1%; P = 0.005) and physical exertion more frequently in HFrEF (1% vs. 0%; P = 0.013). There was also a large category of 'other' non-CV precipitants (11% vs.10%).
The proportions of patients with an unknown reason for HF hospitalization were similar in the two HF groups (14% vs. 13%).
. 
Investigator-identified clinical evidence of heart failure according to type of precipitant
Investigator-identified symptoms and signs at the time of the first hospitalization for HF were similar among the precipitating factor groups, in both HFrEF and HFpEF, with the exception of pulmonary oedema, which was more commonly reported in patients with HFpEF when the precipitating factor was thought to be CV (40% CV, 29% non-CV, 25% unknown precipitant; P = 0.016) ( Figure 1) . The proportions of patients receiving i.v. diuretics (92% HFrEF, 91% HFpEF; P = 0.496) and i.v. vasodilators (16% in both groups; P = 0.935) were similar, but patients with HFrEF were more likely than those with HFpEF to have received i.v. inotropic agents (21% vs. 13%; P < 0.001). Table 3) . Patients with an unknown precipitant were at slightly lower risk for death (both all-cause and CV); this was true in both types of HF (HFrEF and HFpEF) ( Figure 2 ).
Precipitating causes and subsequent mortality
Precipitating causes and subsequent rehospitalization
The picture regarding readmission differed from that for mortality. 
Discussion
The main findings of the current study are: (i) CV reasons were thought to be the precipitant for HF admissions in more than half of cases and non-CV reasons in one-third with the remainder of admissions having no prospectively identified precipitant; (ii) among the CV and non-CV precipitants, there was no single very common and only a few common factors; (iii) the precipitants identified were largely similar for HFrEF and HFpEF, although there were a few differences, and (iv) the type of precipitant (CV or non-CV) was not associated with the subsequent cause of death, but was associated with readmission type.
Investigator-identified precipitating factors leading to heart failure hospitalization
A number of precipitating factors believed to be associated with HF hospitalization have been reported previously, but these have almost exclusively been collected retrospectively. One exception was the RESOLVD pilot study, in which, among 768 patients with HFrEF, the most common primary causes leading to HF hospitalization were thought to be non-adherence to salt restriction (15%), other non-cardiac causes (15%) and inappropriate reductions in HF therapy (9%). 2 Within the 'other' and 'other non-cardiac' precipitating factor categories, investigators noted respiratory infections, use of a beta-blocker (the study drug metoprolol) and excessive fluid intake as the most common causes. Although the proportions of non-cardiac causes and inappropriate reductions in HF therapy were similar in the present study, non-adherence to salt restriction was reported less frequently in CHARM. This difference may be attributable to either patient education efforts regarding salt restriction in the CHARM cohort or alternative primary precipitants (e. more commonly identified in CHARM. Although both CHARM and RESOLVD were multi-site international trials, geographic variability in salt intake may contribute to this difference. In the OPTIMIZE-HF registry of 48 612 patients hospitalized for HF (mean EF: 39%) in the USA, one or more pre-specified precipitating factors were identified in 61% of patients, with pneumonia/respiratory process (15%), myocardial ischaemia (15%) and an arrhythmia (14%) being most frequent. 4 The OPTIMIZE-HF report did not differentiate between patients with HFrEF and those with HFpEF. A more recent international acute HF registry, the Global Research on Acute Conditions Team (GREAT), of 15 828 patients hospitalized for HF in Europe and Asia identified one precipitating factor in 49% of patients, multiple factors in 6% and no known precipitants in 44%. Of those with a single precipitating factor, the most commonly reported precipitants were acute coronary syndrome (52%), atrial fibrillation (16%) and infection (14%). 10 The higher rates of precipitant infection and myocardial ischaemia in the acute HF registries compared with CHARM may be related to the difference between an acute HF registry and a chronic HF clinical trial dataset. Because the present analysis is based on adjudicated HF hospitalizations, myocardial infarctions complicated by acute HF would have been adjudicated as myocardial infarction, rather than HF hospitalization, based on the predefined event definitions, and respiratory infections without significant concomitant volume overload may not have qualified as HF admissions. Recently, registry data from the US Get With The Guidelines-HF database, a prospective observational study of patients hospitalized for HF with documented EF, indicated that the most common factors thought to precipitate HF hospitalizations included pneumonia/respiratory problems (28%), arrhythmia (22%), medication non-compliance (16%), worsening renal failure (15%) and uncontrolled hypertension (15%). 5 Some of these factors varied by EF group (EF: <40%, 40-49%, ≥50%) and were independently associated with hospital length of stay and inpatient mortality. Long-term outcomes were not reported. This registry also identified higher rates of respiratory infection, arrhythmias, medication non-compliance, worsening renal function and hypertension than the present study. Although the leading precipitating factors were similar to those reported here, the proportions in these groups were higher than in CHARM. Registry cohorts may differ from clinical trial cohorts as a result of exclusion criteria, which may select a patient population with generally better renal function, blood pressure control and medication compliance, for instance.
The current findings extend those from prior reports. This study identified a broad spectrum of CV and non-CV reasons thought to have precipitated the index HF hospitalization, with only small differences between patients with HFrEF and those with HFpEF. Several of these factors, both CV-and non-CV-related, are potentially modifiable and could be addressed through close outpatient monitoring, patient education and engagement. Based on the current data, these strategies should include improved management of co-morbidities (atrial fibrillation, hypertension, chronic obstructive pulmonary disease, diabetes), and strategies to improve adherence to evidence-based HF therapies. for HF, although no single intervention alone may be sufficient to address this complex issue. 11 In addition, the number of respiratory infections leading to HF exacerbations, which was one of the leading non-CV reasons in the present study, could potentially be reduced through vaccination programmes for influenza and pneumococcal infections. 12, 13 Given the chronicity and trajectory of HF, some hospitalizations for HF will be unavoidable. However, novel strategies for outpatient management through home visits or clinics for i.v. diuretics have the potential to further reduce hospitalizations for HF, even in the setting of worsening HF.
14
Investigator-identified clinical evidence of heart failure
There were no important differences with respect to symptoms and clinical signs between the precipitant factor groups other than the finding that pulmonary oedema was more commonly reported in HFpEF patients with a CV precipitant. This may be an indicator of a higher degree of volume overload in this subgroup of patients.
Recurrent hospitalizations and mortality
Prior data on long-term outcomes based on precipitants leading to an initial hospitalization for HF are sparse. The present study found that patients with a CV precipitant of their index HF hospitalization had the highest annual incidence rate of CV readmissions, which adds information to the previous report about subsequent risk following a hospitalization for HF. 15 This insight may be relevant both clinically and for research purposes. If a specific CV cause, CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. such as uncontrolled hypertension, can be addressed, subsequent hospitalization could potentially be prevented. Few other studies have investigated the relationship between potential HF hospitalization precipitating factors and risk for readmission and mortality. In the OPTIMIZE-HF registry (n = 5791; mean EF 37%), myocardial ischaemia and worsening renal function were associated with a higher risk for 60-90-day all-cause mortality, whereas uncontrolled hypertension as a precipitating factor was associated with lower rates of post-discharge death or readmission. In the GREAT registry (n = 15 828; mean EF 38%), 90-day all-cause mortality was highest in patients in whom acute HF was thought to have been precipitated by acute coronary syndrome or infection [hazard ratio (HR) 1.69, 95% CI 1.44-1.97; HR 1.51, 95% CI 1.18-1.92, respectively].
10 Analyses were not stratified by EF. In CHARM, rates of CV and all-cause mortality were similar among the three precipitating factor categories in patients with HFrEF and HFpEF, but were overall higher in those with HFrEF, in concordance with prior analyses stratified by EF. 7 The present findings suggest that precipitating factors leading to the initial HF hospitalization may be associated with the rate of recurrent admissions rather than subsequent mortality. This finding may reflect a number of reasons, but it may be that CV precipitants (e.g. atrial fibrillation, myocardial ischaemia) are more persistent or likely to recur than non-CV causes (e.g. respiratory infection). It is also possible that, based on the precipitant, certain conditions may be more or less likely amenable to outpatient management in patients with known HF so that patients re-presenting with CV problems (e.g. arrhythmia) are more likely to be admitted, whereas non-CV problems (e.g. certain infections) may be managed in the outpatient setting.
Limitations
These data should be interpreted in the context of their limitations. Firstly, only the initial HF hospitalization was adjudicated by an independent committee; all subsequent hospitalizations were investigator-reported. It is possible that some of these events would not meet the criteria used by an endpoint committee. In addition, subsequent hospitalizations may have been influenced by the type of precipitant (CV vs. non-CV), whereas mortality was adjudicated in all cases. However, the same data collection forms were used for all events, which should have led to consistent data collection for subsequent events. The removal of additional events would have led to an underestimation of the number of recurrent hospitalizations in this cohort. Secondly, this analysis focused on the primary factor leading to the first adjudicated hospitalization for HF; additional secondary factors were not analysed in this study and precipitating factors leading to subsequent HF hospitalizations were not analysed with respect to CV, non-CV and unknown factors. It is possible that during both the initial and subsequent hospitalizations, multiple factors contributed to patients' worsening HF. In addition, patient-identified precipitating factors for HF hospitalizations may differ from investigator-identified reasons for admission, but the former were not collected in this trial. 16, 17 Thirdly, EFs were reported by the study sites and not verified by an independent core imaging laboratory. Fourthly, the cut-off values for A B Figure 2 Annual incidence rates of events following first heart failure (HF) hospitalization in (A) patients with HF with reduced ejection fraction (≤40%; n = 1152) and (B) patients with HF with preserved ejection fraction (>40%; n = 516). CV, cardiovascular.
HFrEF (EF ≤40%) and HFpEF (EF >40%) in this analysis were based on the study design used in CHARM. The small size of the group with an EF of ≥40% precluded the further division of this group into the recently proposed HF with mid-range EF (40-50%) and HFpEF (EF >50%) classifications. 18 Future investigations in larger cohorts should describe precipitating factors based on the new classifications. Finally, although the present analyses were stratified by EF, no adjustment for potential additional confounders was made in this hypothesis-generating report.
Conclusions
Among chronic HF patients hospitalized for decompensation, the investigator-reported precipitating factor was not associated with the subsequent mortality rate (or cause of death), but was associ- 
